[HTML][HTML] Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target

V Infantino, A Santarsiero, P Convertini… - International journal of …, 2021 - mdpi.com
In order to meet the high energy demand, a metabolic reprogramming occurs in cancer cells.
Its role is crucial in promoting tumor survival. Among the substrates in demand, oxygen is …

[HTML][HTML] Vascular dysfunction in preeclampsia

MA Opichka, MW Rappelt, DD Gutterman, JL Grobe… - Cells, 2021 - mdpi.com
Preeclampsia is a life-threatening pregnancy-associated cardiovascular disorder
characterized by hypertension and proteinuria at 20 weeks of gestation. Though its exact …

[HTML][HTML] Tumor hypoxia regulates immune escape/invasion: influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies

R Abou Khouzam, K Brodaczewska, A Filipiak… - Frontiers in …, 2021 - frontiersin.org
The environmental and metabolic pressures in the tumor microenvironment (TME) play a
key role in molding tumor development by impacting the stromal and immune cell fractions …

[HTML][HTML] Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

NS Vasudev, AR Reynolds - Angiogenesis, 2014 - Springer
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …

[HTML][HTML] Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo

KD Courtney, D Bezwada, T Mashimo, K Pichumani… - Cell metabolism, 2018 - cell.com
Clear cell renal cell carcinoma (ccRCC) is the most common form of human kidney cancer.
Histological and molecular analyses suggest that ccRCCs have significantly altered …

[HTML][HTML] Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets

L Bedford, J Lowe, LR Dick, RJ Mayer… - Nature reviews Drug …, 2011 - nature.com
The ubiquitin–proteasome system (UPS) and ubiquitin-like protein (UBL) conjugation
pathways are integral to cellular protein homeostasis. The growing recognition of the …

[HTML][HTML] Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?

M Catalano, G Procopio, P Sepe, M Santoni… - Pharmacology & …, 2023 - Elsevier
Over the past decade, the management of metastatic renal cell carcinoma (RCC) has
undergone rapid evolution, culminating in a significant improvement in prognosis with …

[HTML][HTML] Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma

H Liu, AR Brannon, AR Reddy, G Alexe, MW Seiler… - BMC systems …, 2010 - Springer
Background MicroRNA regulate mRNA levels in a tissue specific way, either by inducing
degradation of the transcript or by inhibiting translation or transcription. Putative mRNA …

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2

K Yu, C Shi, L Toral-Barza, J Lucas, B Shor, JE Kim… - Cancer research, 2010 - AACR
The mammalian target of rapamycin (mTOR) is a major component of the phosphoinositide
3-kinase (PI3K)/AKT signaling pathway that is dysregulated in 50% of all human …

Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial

F Meric-Bernstam, NM Tannir, O Iliopoulos, RJ Lee… - Clinical Cancer …, 2022 - AACR
Purpose: Dual inhibition of glucose and glutamine metabolism results in synergistic
anticancer effects in solid tumor models. Telaglenastat, an investigational, small-molecule …